BioSpace News Archive

Nearly 1.6 billion people worldwide suffer from anemia, and for the first time new research points to how resistance emerges to the drug dexamethasone used to treat the devastating inherited form of anemia known as Diamond Blackfan anemia (DBA).

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, announced it will report financial results for the fourth quarter and full year 2019 after market close on Thursday, February 13, 2020.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced preliminary unaudited revenue for the full year 2019.

The Board of Directors of Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders

Applied Therapeutics, Inc. announced that it plans to make a public offering of 1,750,000 shares of its common stock, par value $0.0001 per share, in an underwritten registered public offering.

MicroMedicine™, a life sciences technology company and the leader in high throughput microfluidic cell selection, washing, and concentration, is excited to announce the initial steps of a collaboration with HemaCare®, the global leader in human-derived biological products and services.

Centene Corporation announced the final results of the offers to exchange notes issued by WellCare Health Plans, Inc. for up to $1,950,000,000 aggregate principal amount of new notes to be issued by Centene and cash and the related consent solicitations made by Centene on behalf of WellCare to adopt certain proposed amendments to the indentures governing the WellCare Notes.

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces approval from the U.S. Food and Drug Administration (FDA) that the Company has provided sufficient data to support initiating an investigational device exemption (IDE) to evaluate the safety and effectiveness of the DABRA excimer laser system for use as an atherectomy device for the treatment of peripheral vascular stenoses.

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Klinikum Esslingen, a hospital in southern Germany close to Stuttgart, has entered into an agreement to lease and utilize a Senhance® System.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis® CDx test as a companion diagnostic to AstraZeneca’s (LSE/OMX Nordic/NYSE: AZN) and Merck’s PARP inhibitor Lynparza® (olaparib) for men with metastatic castration-resistant prostate cancer.